Computationally optimized broadly reactive antigens for H5N1 and H1N1 influenza viruses
Described herein is the generation of optimized H5N1 and H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on H5N1 and H1N1 influenza isolates. Provided herein are optimized H5N1 and H1N1 influenza HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.
1. A recombinant influenza hemagglutinin (HA) polypeptide, comprising the amino acid sequence of residues 2-566 of SEQ ID NO: 2 or residues 2-568 of SEQ ID NO: 1.
2. The influenza HA polypeptide of claim 1 , consisting of the amino acid sequence of residues 2-566 of SEQ ID NO: 2 or residues 2-568 of SEQ ID NO: 1.
3. The influenza HA polypeptide of claim 1 , comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 1.
4. The influenza HA polypeptide of claim 1 , consisting of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 1.
5. An isolated nucleic acid molecule encoding one of the influenza HA polypeptides of claim 1 .
6. The isolated nucleic acid molecule of claim 5 , wherein the nucleic acid molecule is codon-optimized for expression in mammalian cells.
7. A vector comprising the nucleic acid molecule of claim 5 .
8. The vector of claim 7 , further comprising a promoter operably linked to the nucleic acid sequence encoding the influenza HA polypeptide.
9. An isolated cell comprising the vector of claim 7 .
10. An influenza virus-like particle (VLP) comprising one of the influenza HA polypeptides of claim 1 .
11. The influenza VLP of claim 10 , further comprising an influenza neuraminidase (NA) protein, an influenza matrix (M1) protein, or both.
12. An influenza VLP comprising one of the influenza HA polypeptides of claim 1 , produced by transfecting a host cell with a vector encoding the HA polypeptide, a vector encoding an influenza NA protein and a vector encoding an influenza M1 protein under conditions sufficient to allow for expression of the HA, M1 and NA proteins.
13. A fusion protein comprising one of the influenza HA polypeptides of claim 1 .
14. A composition comprising the VLP of claim 10 and a pharmaceutically acceptable carrier.
15. A method of eliciting an immune response in a subject to a H1 or H5 influenza virus, comprising administering an effective amount of the VLP of claim 10 ;
wherein when the VLP comprises the recombinant influenza HA polypeptide comprising the amino acid sequence of residues 2-566 of SEQ ID NO: 2, and an immune response against an H1 influenza virus is elicited; or
wherein when the VLP comprises the recombinant influenza HA polypeptide comprising the amino acid sequence of residues 2-568 of SEQ ID NO:1, and an immune response against an H5 influenza virus is elicited.
16. The method of claim 15 , wherein the composition further comprises an adjuvant.
17. The method of claim 15 , wherein the composition is administered intramuscularly.
18. The method of claim 15 , wherein the composition comprises about 1 to about 25 μg of the VLP.
19. The method of claim 18 , wherein the composition comprises about 15 μg of the VLP.